Search

Search Constraints

You searched for: Author/Creator Sebag, Michael

Search Results

1. Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. (6th October 2019)

2. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Issue 10027 (9th April 2016)

3. Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada. (27th June 2021)

4. Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment. Issue 4 (30th September 2022)

5. Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database. Issue 4 (31st August 2022)

6. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. Issue 1 (8th November 2020)

7. Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. (5th April 2022)

9. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022)

10. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Issue 6 (12th May 2022)